Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 5/20 | 0.76 |
| ▸ | ELANE | P08246 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | MAP3K14 | Q99558 | 9/20 | 0.53 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30695134 | 1.00 | SCN9A (0.76) | SCN9AELANEKMT2AMAPTCASP1 | |
| SCHEMBL14518066 | 0.90 | SCN9A (0.64) | SCN9AELANEKMT2AMAPTCASP1 | |
| SCHEMBL15882042 | 0.88 | SCN9A (0.69) | SCN9AELANEKMT2AMAPTCASP1 | |
| SCHEMBL9988378 | 0.87 | SCN9A (1.00) | SCN9AELANEKMT2AMAPTCASP1 | |
| SCHEMBL7421574 | 0.86 | SCN9A (0.58) | SCN9AMAPTRORCKDM4EALDH1A1 | |
| SCHEMBL28349333 | 0.85 | SCN9A (0.59) | SCN9AELANEMAP3K14 | |
| SCHEMBL16517440 | 0.84 | SCN9A (0.57) | SCN9AELANEMAP3K14 | |
| SCHEMBL30668595 | 0.82 | SCN9A (0.59) | SCN9AELANEMAP3K14 | |
| SCHEMBL31175792 | 0.81 | SCN9A (0.61) | SCN9AELANEMAP3K14 | |
| SCHEMBL30142275 | 0.80 | SCN9A (0.56) | SCN9AELANEMAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105408321-B | Indoles and azole derivatives, their preparation method and the pharmaceutical composition containing them | 法国施维雅药厂 | 2019-03-08 | — | — | CN | disclosed |
| US-7482342-B2 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2009-01-27 | — | — | US | disclosed |
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | SANOFI-AVENTIS (FR) | 2006-01-05 | — | — | US | disclosed |
| US-6458781-B1 | BLOCKERS CALCIUM CHANNEL ANTAGONISTS FOR STROKES, BRAIN DISORDERS | WARNER-LAMBERT COMPANY | 2002-10-01 | — | — | US | disclosed |
| WO-1999055688-A1 | SUBSTITUTED DIARYLALKYL AMIDES AS CALCIUM CHANNEL ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004000-A1 | Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors | CDK2, CDK1, CDK4 | SCN9A 3105/4885ELANE 3434/4885KMT2A 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.